Jayastu Senapati

1.4k total citations · 1 hit paper
77 papers, 480 citations indexed

About

Jayastu Senapati is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Jayastu Senapati has authored 77 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hematology, 39 papers in Public Health, Environmental and Occupational Health and 29 papers in Genetics. Recurrent topics in Jayastu Senapati's work include Acute Lymphoblastic Leukemia research (38 papers), Chronic Myeloid Leukemia Treatments (32 papers) and Acute Myeloid Leukemia Research (30 papers). Jayastu Senapati is often cited by papers focused on Acute Lymphoblastic Leukemia research (38 papers), Chronic Myeloid Leukemia Treatments (32 papers) and Acute Myeloid Leukemia Research (30 papers). Jayastu Senapati collaborates with scholars based in United States, India and China. Jayastu Senapati's co-authors include Hagop M. Kantarjian, Elias Jabbour, Nicholas J. Short, Tapan M. Kadia, Koji Sasaki, Farhad Ravandi, Ghayas C. Issa, Jerald P. Radich, Fadi Haddad and Jeffrey H. Lipton and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Jayastu Senapati

64 papers receiving 478 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Management of chronic myeloid leukemia in 2023 – common ground and common sense

2023 73 citations Jayastu Senapati, Koji Sasaki et al. Blood Cancer Journal profile →

Peers

Jayastu Senapati

HEMAT

PHEOH

ONCOL

GENET

Kristen Pettit United States

Eva Hoke United States

Isabelle Luquet France

Nosha Farhadfar United States

Yoo Jin Lee South Korea

Marc Schwartz United States

Giambattista Bertani Italy

Esther N. Oliva Italy

Min‐Yuan Wu China

Wilson Grandin United States

Kristen Pettit United States

Jayastu Senapati

320 ×1.0

HEMAT

64 ×0.3

PHEOH

71 ×0.4

ONCOL

187 ×1.6

GENET

221 ×2.1

Citations per year, relative to Jayastu Senapati Jayastu Senapati (= 1×) peers Kristen Pettit

Countries citing papers authored by Jayastu Senapati

Since Specialization

Citations

This map shows the geographic impact of Jayastu Senapati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jayastu Senapati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jayastu Senapati more than expected).

Fields of papers citing papers by Jayastu Senapati

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jayastu Senapati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jayastu Senapati. The network helps show where Jayastu Senapati may publish in the future.

Co-authorship network of co-authors of Jayastu Senapati

This figure shows the co-authorship network connecting the top 25 collaborators of Jayastu Senapati. A scholar is included among the top collaborators of Jayastu Senapati based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jayastu Senapati. Jayastu Senapati is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kantarjian, Hagop M., Nicholas J. Short, Nitin Jain, et al.. (2025). Hyper‐CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome‐Negative B‐Cell Acute Lymphoblastic Leukemia. American Journal of Hematology. 100(3). 402–407. 6 indexed citations

Kantarjian, Hagop M., Nitin Jain, Jayastu Senapati, et al.. (2025). Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia. Blood. 146(Supplement 1). 5131–5131.

Senapati, Jayastu, Tapan M. Kadia, Naval Daver, et al.. (2025). Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges. Cancer. 131(7). e35806–e35806. 3 indexed citations

Senapati, Jayastu, H. Kantarjian, Edward Ayoub, et al.. (2024). Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up. Blood. 144(Supplement 1). 1513–1513. 1 indexed citations

Senapati, Jayastu & Elias Jabbour. (2024). Dar-ting at CD38 in T-cell leukemias. Blood. 144(21). 2162–2164. 1 indexed citations

Bataller, Álex, Hagop M. Kantarjian, Alexandre Bazinet, et al.. (2024). Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. Blood. 144(Supplement 1). 56–56. 3 indexed citations

Senapati, Jayastu, Hagop M. Kantarjian, Fadi Haddad, et al.. (2024). Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation. American Journal of Hematology. 100(2). 249–259. 3 indexed citations

Ravandi, Farhad, Jayastu Senapati, Nitin B. Jain, et al.. (2024). Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 38(12). 2717–2721. 8 indexed citations

Arora, Sankalp, Jayastu Senapati, Lucia Masárová, et al.. (2024). Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF).. Journal of Clinical Oncology. 42(16_suppl). 6572–6572. 1 indexed citations

10.

Short, Nicholas J., Nitin Jain, Jayastu Senapati, et al.. (2024). ALL-808 Very Promising Results of the Dose Dense (D-D) Mini-Hyper-CVD-Inotuzumab-Blinatumomab Phase 2 Trial in Patients with Relapsed-Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 24. S284–S285. 6 indexed citations

11.

Senapati, Jayastu, Hagop M. Kantarjian, Alexandre Bazinet, et al.. (2024). Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer. 130(19). 3333–3343. 8 indexed citations

12.

Loghavi, Sanam, Farhad Ravandi, Courtney D. DiNardo, et al.. (2024). Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT -Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic Mastocytosis. Blood. 144(Supplement 1). 2857–2857.

13.

Senapati, Jayastu, Elias Jabbour, Nicholas J. Short, et al.. (2024). Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 1442–1442. 3 indexed citations

14.

Jabbour, Elias, Jayastu Senapati, Fadi Haddad, et al.. (2024). A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse. Blood. 144(Supplement 1). 3156–3156. 1 indexed citations

15.

Senapati, Jayastu, Sanam Loghavi, Nicholas J. Short, et al.. (2023). Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 142(19). 1647–1657. 35 indexed citations

16.

Jabbour, Elias, Fadi Haddad, Nicholas J. Short, et al.. (2023). Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 143(5). 417–421. 25 indexed citations

17.

Senapati, Jayastu, Koji Sasaki, Ghayas C. Issa, et al.. (2023). Management of chronic myeloid leukemia in 2023 – common ground and common sense. Blood Cancer Journal. 13(1). 58–58. 73 indexed citations breakdown →

18.

Senapati, Jayastu, Tapan M. Kadia, & Farhad Ravandi. (2023). Maintenance therapy in acute myeloid leukemia: advances and controversies. Haematologica. 108(9). 2289–2304. 17 indexed citations

19.

Senapati, Jayastu, Mahran Shoukier, Guillermo Garcia‐Manero, et al.. (2022). Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. American Journal of Hematology. 97(5). 574–582. 15 indexed citations

20.

Senapati, Jayastu, et al.. (2014). Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated Acute Myeloid leukemia- A case report and review of literature. Mediterranean Journal of Hematology and Infectious Diseases. 6(1). e2014016–e2014016. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact